Biotech News
Related news
PCVXVaxcyte2026-10-04 21:00 EST
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
PCVXVaxcyte2026-10-05 20:28 EST
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
VXRTVaxart2026-03-12 20:05 EST
Vaxart Provides Business Update and Reports Full Year 2025 Financial Results
GSKGSK plc2026-01-26 07:00 EST
GSK’s RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older
Vaxcyte
Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...
Recent company news
PCVXVaxcyte2026-10-07 02:49 EST
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
PCVXVaxcyte2026-10-05 20:28 EST
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
PCVXVaxcyte2026-10-05 10:00 EST
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
PCVXVaxcyte2026-10-04 21:00 EST
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
PCVXVaxcyte2026-09-03 20:05 EST
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Stock data
- Close
- 66.70 USD
- Market cap
- 6.85B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States